FIELD: veterinary medicine.
SUBSTANCE: present invention relates to a method for diagnosing degenerative mitral valve disease in an animal from the canine family. The method includes measuring the normalized relative abundance of Faecalibacterium as a biomarker and at least one other biomarker selected from a group consisting of Erysipelatoclostridium, Butyricicoccus, Ruminococcaceae UCG014 and their combinations; and determining the presence of an early stage DMVD in an animal from the canine family if Faecalibacterium has a normalized relative abundance from 0 to 0.1, and if the specified the value is 0, then the stage of congestive heart failure (CHF) is determined in the animal, and an additional definition of the specified early stage of DMVD based on additional biomarkers selected from a group consisting of Ruminococcaceae UCG014, Butyricicoccus and Erysipelatoclostridium, where Ruminococcaceae UCG014 has a normalized relative abundance from 0 to 0.1 and at the same time the animal does not have clinical symptoms of the CHF stage, where Butyricicoccus has a normalized relative abundance from 0 to 0.1 and at the same time the animal does not have clinical symptoms of the CHF stage and where Erysipelatoclostridium has a normalized relative abundance from 0 to 0.5 and at the same time the animal does not have clinical symptoms of the CHF stage.
EFFECT: invention makes it possible to effectively diagnose mitral valve disease at an early stage in an animal of the canine family.
3 cl, 1 tbl, 1 ex
